Navigation Links
Sorafenib Shows Promise for Heart-Lung Disease

Cancer drug interferes with abnormal cell growth seen in pulmonary hypertension

TUESDAY, May 20 (HealthDay News) -- The cancer drug sorafenib (Nexavar) shows promise as a treatment for pulmonary hypertension, according to a University of Chicago Medical Center study.

During the study, nine patients took the drug for 16 weeks at doses lower than those given to cancer patients. The patients also continued to take their standard medications.

Eight of the patients increased their ability to exercise, six showed significant improvements in their right ventricular ejection fraction (the ability of the heart to pump blood to the lungs), and four had a significant decrease in pulmonary artery pressures.

The most common side effects were diarrhea and hair loss.

The findings were expected to be presented May 20 at the American Thoracic Society annual meeting, in Toronto.

"This is not a disease where we are used to seeing people who have been stable on the strongest medications we have suddenly get better. We have drugs that may slow progression of the disease, but nothing that can stop or reverse the process," study author Dr. Mardi Gomberg-Maitland, an assistant professor of medicine, said in a prepared statement.

"To see these improvements in such a short time is quite promising. Although evaluation of this drug is at a very early stage, and this study focused on safety and tolerability, we are genuinely excited about the results," Gomberg-Maitland said.

Sorafenib was originally developed at the University of Chicago as a treatment for kidney cancer. Both cancer and pulmonary hypertension involve abnormal cell growth. In pulmonary hypertension, the abnormal cell growth occurs in blood vessels that lead to the lungs, causing the vessels to thicken and narrow. This means the heart has to work harder to pump blood to the lungs. This extra workload damages the heart.

Sorafenib appears to interfere with the abnormal cell growth seen in pulmonary hypertension.

Researchers are now organizing a multi-center trial of the drug in patients with pulmonary hypertension.

More information

The U.S. National Heart, Lung, and Blood Institute has more about pulmonary hypertension.

-- Robert Preidt

SOURCE: University of Chicago Medical Center, news release, May 19, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Sorafenib Slows Growth of Some Leukemias
3. With age comes a sense of peace and calm, population research center study shows
4. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
5. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
6. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
7. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
8. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
9. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
10. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
11. Research shows HPV testing offers women protection for twice as long as smear testing
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology: